Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

NCT05176483 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT05176483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05176483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2021
Completion date
June 28, 2030
Enrollment
1,394 (estimated)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma (ccrcc), colorectal cancer (crc), drug-drug interaction (ddi), head and neck squamous cell carcinoma (hnscc), hepatocellular carcinoma (hcc), metastatic castration-resistant prostate cancer (mcrpc), non-clear cell renal cell carcinoma (nccrcc), non-small cell lung cancer (nsclc), renal cell carcinoma (rcc), solid tumor, urothelial carcinoma (uc)